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AbstrACt
Objectives In sub-Saharan Africa, substantial 
international funding along with evidence-based clinical 
practice have resulted in an unparalleled scale-up of 
access to antiretroviral treatment at a higher CD4 count. 
The role and timing of highly active antiretroviral therapy 
(HAART) in mediating cervical disease remains unclear. The 
aim of this article is to systematically review all evidence 
pertaining to Africa and identify research gaps regarding 
the epidemiological association between HAART use and 
the presence of premalignant/malignant cervical lesions.
Method Five databases were searched until January 2017 
to retrieve relevant literature from sub-Saharan Africa. 
Publications were included if they addressed prevalence, 
incidence or clearance of human papillomavirus (HPV) 
infection in women undergoing HAART as well as 
cytological or histological neoplastic abnormalities.
results 22 studies were included, of which seven were 
prospective studies. Women receiving HAART are less 
likely to develop squamous intraepithelial lesions (SILs). 
There is evidence that duration of HAART along with 
the CD4 count may reduce the prevalence of high-risk 
HPV (HR-HPV), suggesting that without HAART, severe 
immunosuppression increases the risk of becoming or 
remaining infected with HR-HPV. Furthermore, according 
to existent literature, the CD4 count, rather than HAART 
coverage or its duration, plays a central role in the 
prevalence of cervical intraepithelial neoplasia (CIN) 2 and 
CIN 3.
Conclusion Our findings suggest a positive impact of 
HAART duration, in conjunction and interaction with 
CD4 count, on reducing the prevalence of HR-HPV. 
The greatest treatment effect might be seen among 
women starting at the lowest CD4 count, which may 
have a more instrumental role in cervical oncogenesis 
than either HAART use or the treatment duration on the 
prevalence of CIN 2 and CIN 3. There is still insufficient 
evidence to show a clear association between HAART 
coverage and the incidence of invasive cervical 
cancer. Enhanced surveillance on the impact of HAART 
treatment is crucial.
IntrOduCtIOn
Cervical cancer is the second most common 
female malignancy and the leading cause of 
death from cancer in women worldwide, of 
which 85% of cases occur in low and middle 
income countries.1 The human papillo-
mavirus (HPV), one of the most common 
sexually transmitted infections, is now 
well established as the aetiological agent. 
‘High-risk’ (HR) HPV DNA has been found 
to be present in 99.7% of cervical cancers 
worldwide.2 Over 200 HPV genotypes have 
been identified and are divided into HR 
and low-risk (LR) carcinogens, depending 
on their potential to cause cancer.
strengths and limitations of this study
 ► Comprehensive review within five databases on a 
major public health concern for women’s health.
 ► Contributes to and summarises the evidence of the 
role of CD4 count and highly active antiretroviral 
therapy (HAART) use in the progression to cervical 
disease for women who are HIV-positive in Africa.
 ► High variability in the sample size of the retrieved 
studies, therefore difficult to give the right weight to 
the current evidence.
 ► Heterogeneity in the sensitivity or specificity 
of screening methods may also render results 
less comparable; in some studies, HIV status of 
participants may not have been accurately measured, 
leaving the possibility of misclassification.
 ► Lack of prospective studies, with a  clear strategy 
to deal with the loss to follow-up, retrieved by 
the literature search using the same definition of 
regression and progression of cervical disease; 
therefore the criterion of temporality for causality is 
not well fulfilled.
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Invasive cervical cancer (ICC) and its precursor, 
cervical intraepithelial neoplasia (CIN), are associated 
with persistent infection with HR HPV genotypes. Prod-
ucts of HPV oncogenes E6 and E7 alter normal genetic 
and cellular functions and induce malignant transforma-
tion. HPV infections are usually transient, and even those 
that persist for a few months are usually cleared naturally, 
however women infected with HIV are at higher risk of 
contracting HPV and developing squamous intraepithe-
lial lesions (SILs), the precursor of cervical cancer.3 4 
In this population, this type of lesion tends to be more 
aggressive, persistent and more likely to recur following 
cervical disease treatment.5 6
In sub-Saharan Africa, the region with the highest prev-
alence of HIV one and HIV two in the world, the current 
standard recommendations for first-line adult antiretro-
viral therapy include two nucleoside reverse transcriptase 
inhibitors (NRTIs) and one non-nucleoside reverse tran-
scriptase inhibitor (NNRTI).7 Protease inhibitors (PIs) 
are primarily reserved for second-line treatment due 
to issues of cost, dosing frequency, drug–drug interac-
tions, potential for long-term side effects and higher pill 
burden. Persons not responding to first-line regimens are 
usually switched to a cocktail of two NRTIs plus a boosted 
PI.8
While the use of HAART decreased the risk of Kaposi 
sarcoma and non-Hodgkin's lymphoma, both AIDS-in-
duced cancers,9 there was no significant change in the 
incidence of cervical cancer.10–12 Moreover, studies on the 
impact of HAART on the natural history of cervical SILs 
have yielded inconsistent results.13 14Moreover, most 
studies have been conducted in industrialised settings 
and not in sub-Saharan Africa, the area hardest hit by the 
global HIV/AIDS pandemic, home to nearly 25 million 
people living with HIV/AIDS.15
While the use of HAART might be expected to reduce 
the incidence of cervical cancer and progression of 
cervical dysplasia as a result of improved immunolog-
ical function, as women are accessing HAART, their life 
expectancy will increase, due to less competing risk of 
dying from an opportunistic infection, which in turn may 
put them more at risk for ICC.16 These two reasons will 
augment their risks of a premalignant condition to trans-
form into an ICC. Inversely, prolonged use of HAART 
might potentially prevent the acquisition of HR-HPV 
and/or evolution to ICC.
In the HAART policy landscape, there have been recent 
shifts towards earlier initiation of treatment. Until 2009, 
the WHO recommendations for sub-Saharan Africa stipu-
lated initiation of antiretroviral treatment at a CD4 count 
threshold of 200 cells/mm3 in order to further reduce the 
risk of HIV transmission to others. However, this guideline 
was revised in 2009 and initiation of antiretroviral therapy 
recommended at CD4 counts of 350 cells/mm³, only to 
be revised in 2013 and the treatment threshold set to 
500 cells/mm³ or less.17 The policy was again recently 
revised and treatment initiation recommended for all 
adults with HIV infection adults, regardless of WHO 
clinical stage or CD4 cell count, following the results of 
the START trial.18
As a research gap, it remains to be determined whether 
HAART could improve control of and reduce the burden 
of HPV infection and the associated precancerous states 
if initiated even earlier in the course of HIV infection.19 
The role and timing of HAART in mediating this relation-
ship has been difficult to study and remains unclear.20 21 
The objectives of this paper are to review the existing 
evidences on the association between the use of HAART 
and presence of HPV infection and premalignant/malig-
nant cervical lesions.
MethOdOlOgy
We conducted this systematic review based on a pre-de-
fined search protocol that conformed to the criteria set 
out by the PRISMA statement (see Research Checklist).22 
CINAHL, SCOPUS, Global Health, PubMed and Embase 
databases were searched (figure 1).
search terms
The domains of the search terms were antiretroviral 
therapy, human papillomavirus, abnormal cytology, 
cervical dysplasia, cervical cancer and sub-Saharan Africa 
(see online  supplementary file 1).
Inclusion criteria
Article selection criteria included any clinic-based 
randomised controlled trials (RCTs), meta-analyses/
systematic reviews, observational or population-based 
linkage studies documenting both HAART status and 
HPV/CIN/ICC rates in sub-Saharan Africa. The five data-
bases mentioned above were searched in January 2017 for 
articles published from January 1997 onwards to limit the 
publications to the combined HAART era. The following 
types of articles were excluded from our search: case 
reports, articles that did not include combination antiret-
roviral therapy, risk factors for CIN 2+ or did not stratify 
data by HAART users. We limited our search to English 
language literature.
study selection
We considered the following four components (Popu-
lation, Intervention, Comparison, Outcome—PICO) to 
assess and categorise studies to be included in this review.
Population: the population eligible for this study 
includes women with HIV infection or women with 
AIDS with concomitant HPV infection and/or with 
various degrees of abnormal cytology diagnosed through 
a recognised method such as PCR HPV genotyping, 
cytology, visual inspection with acetic acid (VIA), visual 
inspection with Lugol’s iodine (VILI) and histologically 
confirmed biopsies, and living in sub-Saharan countries.
Intervention: the intervention examined in this study 
is the administration of HAART, defined as at least three 
antiretroviral drugs belonging to two drug classes (NRTI, 
NNRTI or PI) and (if possible) the duration of treatment.
Comparison: comparison is made between women not 
receiving HAART and women receiving HAART.
group.bmj.com on January 31, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
 3Menon S, et al. BMJ Open 2017;7:e015123. doi:10.1136/bmjopen-2016-015123
Open Access
Outcome(s): The wide spectrum of cervical diseases, 
ranging from the HPV infection (and its potential 
clearing) through cervical oncogenesis and precursor 
lesions at the lower end of the neoplastic spectrum, to 
invasive cervical dysplasia.
All potentially relevant publications were evaluated by 
two reviewers (SM and RR) and were included in this 
review if they addressed any of the following outcomes: 
(1) prevalence, incidence of onset or clearance of HPV 
infection in women on HAART; (2) prevalence of cervical 
cytological or histological neoplastic abnormalities or 
ICC in HAART users. Possible cases of disagreement 
about the inclusion or exclusion of articles were resolved 
on an individual basis via thorough discussion among the 
authors of the justification for exclusion/inclusion.
With the exception of steps concerning the quantitative 
synthesis (meta-analysis), the PRISMA 2009 checklist and 
flow diagram23 were used to screen and include studies. 
We also enriched the search by reviewing reference lists 
from retrieved publications to identify additional manu-
scripts not captured by the searches. In reporting the 
results, we used the original terminology as stated in the 
original articles.
Duplication removal: the original searches from all 
the databases were combined in an EndNote library 
(EndNote version 8, San Francisco, California, USA) and 
all duplicates removed.
extraction of relevant information from the selected studies
For all publications, SM and RR recorded the following 
variables: study location, year of study, study design, study 
population, main exposure of interest, main outcome of 
interest, confounding factors adjusted for and main find-
ings.
Data assessment
Because of the lack of randomised trials retrieved (due 
to ethical considerations), we considered prospective/
longitudinal studies of the highest quality. We reported an 
overall score (from 3 to 1) based on our assessment of the 
overall quality of evidence for the following parameters: 
(1) minimisation of selection bias: (score ‘3’= strong) the 
participants were likely, (score ‘2’= moderate) somewhat 
likely, (score ‘1’ = weak) not likely to represent the target 
population. (2) Study design: (score ‘3’ = strong) prospec-
tive study and large sample size (higher than 200)23; a 
prospective study with a sample size lower than 200 and a 
cross-sectional study with a sample size >200 (score ‘2’ = 
moderate); and a cross-sectional study with a sample size 
under 200 (score ‘1’ = weak). (3) Diagnostic accuracy: 
(score ‘3’) strong histopathological diagnosis; moderate 
(score ‘2’) VIA/VILI using colposcopy with biopsy solely 
in cases when lesions appeared suspicious for CIN; and 
weak (score ‘1’) cytological diagnosis. (4) Confounders: 
(score ‘3’) strong, controlled for all relevant confounders; 
(score ‘2’) moderate, controlled for some confounders; 
(score ‘1’) weak, control for confounders not specified. 
(5) Withdrawals, loss to follow-up and dropouts: (score 
‘3’) strong, description of a strategy to minimise the loss to 
follow-up, reported withdrawals and dropouts (80–100% of 
participants completed the study)24; (score ‘2’) moderate, 
reported withdrawals and dropouts; (60% of participants 
completed the study); (score ‘1’) weak, withdrawal and 
dropout rates not specified.
We assessed the methodological quality of evidence by 
calculating the mean of each study and attributing the 
mean one of the qualitative attributes, strong, moderate, 
and weak.
results
On 15 January 2017, we included 22 studies in this review 
(figure 1). No disagreement appeared between the 
two main coauthors about the studies to be included. 
A summary of the study is presented in table 1.
Figure 1 Flowchart with steps to retrieve the studies to include in the review.
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study population
A total of 19 345 women with HIV infection were included 
in the studies retrieved and included in this review (one 
study was an ecological study which did not report the 
individual sample size). The sample sizes for these studies 
ranged from 70 to 3241 women with HIV infection.
study design
The published literature on HAART and HR HPV pres-
ence and cervical dysplasia is characterised by a lack of 
standardisation in study designs. Twelve studies were 
cross sectional, two case-control, seven were prospective 
cohorts and one was a time-series ecological study.
geographical location
Two studies were conducted in Nigeria; four in Kenya; 
seven in South Africa; one in Ethiopia; two in Uganda; 
two in Cameroon; one in Benin; one in Tanzania; one in 
Ivory Coast; and one in Burkina Faso (see table 2).
Quality assessment of studies
The overall quality of evidence ranged from weak/
moderate (score of 1.5) to strong (score of 3) (table 1). 
Five studies had an average score below 2 and the quality 
of their evidence was considered as ‘weak to moderate’; 
15 studies had a score above 2 but less than 3 and the 
quality of their evidence was considered as ‘moderate’ or 
‘moderate to strong. Just one study had a full score of 3 
and was considered as ‘strong’. One study was ecological 
in design and could not be assessed in the same way as the 
other studies that analysed individual data. The quality 
of evidence was mostly downgraded due to the cross-sec-
tional nature of the studies as well as the lack of studies 
where samples have been histopathologically confirmed.
We discuss these differences by stage of disease: 
(1) HAART and HR HPV infection; (2) HAART and SIL/
CIN; (3) HAART and ICC, and outline trends and differ-
ences.
summary of studies on the epidemiological association 
between hAArt and hr hPV infection/prevalence
Four studies found a significant and inverted association 
between HAART use and HR HPV infection/prevalence. 
De Vuyst et al (Kenya, 2012)25 reported that the preva-
lence of HR HPV linearly decreased with use and duration 
of HAART (p=0.011). This association becomes more 
evident when this analysis is stratified by CD4 count 
categories. While the prevalence of HR HPV among 
patients not receiving HAART linearly increased with 
each decrease in CD4 count category (CD4 <200; CD4 
200–349; CD4 350–499; and CD4≥500; PR for linear trend 
5.03, p=0.025), this trend was only marginally significant 
Table 1 Summary of the quality of evidence assessment for the included studies
First author
Minimisation of 
selection bias Study design
Diagnostic 
accuracy
Control of 
confounders
Loss to 
follow-up
Overall methodological score 
and quality
Mogtomo M strong weak weak weak N/A 1.5 (weak to moderate)
Ononogbu U strong moderate weak weak N/A 1.8 (weak to moderate)
Ezechi O. C strong moderate weak strong N/A 2.3 (moderate to strong)
Ezechi O. C strong moderate strong strong N/A 2.8 (moderate to strong)
McKenzie KP strong moderate weak weak N/A 1.8 (weak to moderate)
Huscko M strong moderate moderate strong N/A 2.5 (moderate to strong)
De Vuyst H strong moderate strong strong N/A 2.8 (moderate to strong)
Gedefaw A strong moderate weak strong N/A 2.3 (moderate to strong)
Mutyaba I * N/A N/A N/A N/A N/A N/A
Firnhaber C strong strong weak strong weak 2.2 (moderate to strong)
Memiah P strong moderate moderate weak N/A 2.0 (moderate)
Rositch A strong Strong strong strong weak 2.6 (moderate to strong)
Omar T strong strong weak strong strong 2.6 (moderate to strong)
Adler DH strong strong weak strong weak 2.2 (moderate to strong)
Zeier MD strong strong strong strong weak 2.6 (moderate to strong)
Bekolo CP strong moderate moderate strong N/A 2.5 (moderate to strong)
Chichi Capo CV strong weak strong weak N/A 2.0 (moderate)
van Bogaert LJ strong moderate strong weak N/A 2.0 (moderate)
Mwakigonja  AM strong moderate weak weak N/A 1.8 (weak to moderate)
Jacquet A strong moderate moderate strong N/A 2.5 (moderate to strong)
Katumba AC strong moderate weak weak N/A 1.8 (weak to moderate)
Kelly HA strong strong strong strong strong 3.0 (strong)
*Ecological study, not amenable to quality assessment since this study is population based and not individual based.
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among women receiving HAART for <2 years (prevalence 
ratio (PR) for linear trend 2.98, p=0.084) and insignif-
icant for women on HAART therapy for ≥2 years (PR 
for linear trend 1.19, p=0.275). Zejer et al (South Africa 
2015)26 reported a significant reduction in risk of HPV in 
women on HAART (OR 0.23, 95% CI 0.15 to 0.37) in the 
204 patients eligible for HAART, and for every additional 
month of HAART since initiation, the risk of detection of 
any HPV type decreased by 9%.
Kelly et al (Burkina Faso and South Africa, 2017)27 
observed that, compared with long-duration antiretro-
viral therapy users (>2 years), HR HPV prevalence was 
higher among those on short duration HAART in both 
countries. However, when adjusted for CD4 cell count, 
this association was observed in Burkina Faso only (65.1 
vs 52.1% for <2 years compared with >2 years; aPR¼1.24, 
95% CI 1.04 to 1.47). Ezechi et al (Nigeria, 2014) reported 
lower HR HPV prevalence in women who were HIV posi-
tive on antiretroviral drugs (OR=0.4; 95% CI: 0.3 to 0.5).
Whereas four studies found a significant epidemiolog-
ical association between HAART and HR HPV genotypes, 
one did not. Rositch et al. (Uganda, 2013)28 did not find 
any impact on monthly HPV DNA detection (PR 1.0; 
95% CI 0.96 to 1.08), regardless of immune reconstitution 
or HIV viral suppression. Almost all test subjects (92%) 
had detectable HPV in the 6 months preceding HAART 
initiation and the cumulative prevalence remained high 
following initiation of therapy (90%) after a follow-up of 
6 months (table 2).
The review revealed heterogeneity between studies in 
the use of the screening/diagnostic methods for cervical 
pathology (table 3). Nine studies used cytological changes 
with reporting based on the revised Bethesda classifica-
tion, two studies used histopathological confirmation, 
and five studies used VIA/VILL screening methods of 
which three ascertained disease using colposcopy with 
biopsy solely in cases when lesions appeared suspicious 
for CIN.
Seven cross-sectional studies reported on the frequency 
of SIL and risk factors for SIL. Memiah et al. (Kenya, 
2012)29 observed that patients not receiving HAART 
treatment were 2.2 times more likely to have precan-
cerous lesions than patients receiving HAART (adjusted 
OR=2.21, 95% CI 1.28 to 3.83). Similarly, Mogtomo et al 
(Cameroon, 2009)30 reported that, of 22 high-grade SIL 
(HSIL)-positive women included in the study, 63.6% 
(14/22) were not on HAART, whereas 36.4% (8/22) 
were receiving HAART. The study revealed that total 
cervical abnormalities (HSIL and low-grade SIL (LSIL)) 
had a prevalence of 48.6% (n=17) among HAART users 
compared with 62.9% among women not receiving 
HAART (p=0.034).
In line with the association between the absence of 
HAART treatment and development of SIL, O. Ezechi 
et al (Nigeria, 2013) showed an increased risk of both 
SIL (adjusted OR=2.0; 95% CI 1.2 to 3.5) and HSIL 
(adjusted OR=2.6; 95% CI 1.0 to 6.7)31 among 1140 
participants not on HAART, adjusted for age, marital 
status, age at first intercourse and lifetime sexual 
partners. Nevertheless, Ononogbu et al (Nigeria, 
2013) found only marginal or insignificant associa-
tions with different HAART regimens.32 Their study 
reported that 2501 women on tenofovir-containing 
HAART had a borderline significant RR of 1.4 (95% 
CI 1.0 to 2.0), and a RR of 1.5 (95% CI 1.0 to 2.2) on 
zidovudine-containing HAART, whereas women on 
stavudine-containing HAART showed a RR of 0.9 (95% 
CI 0.4 to 2.11) of having cervical disease compared with 
women not receiving HAART.29
Hushko et al (Kenya, 2014)33 observed that combined 
oral contraceptives remained significantly associated 
with detection of CIN 2+ in women on HAART (adjusted 
OR=1.84; 95% CI 1.20 to 2.82), compared with in women 
not HAART (adjusted OR=1.72; 95% CI 1.08 to 2.73), 
whereas the use of a progesterone implant was associated 
with increased detection of CIN 2+ (adjusted OR=9.43; 
95% CI 2.85 to 31.20) only among women not on HAART. 
McKenzie et al (Kenya, 2011)34, who explored risk factors 
for SIL development in women on HAART, reported no 
significant difference in the use of neviparine-based regi-
mens compared with efavirenz-based regimens between 
women with normal cytology and those with SIL (74% vs 
72%; p=0.80). Similarly, there was no difference in the 
prevalence of nucleoside reverse transcriptase inhibitors 
backbones containing zidovudine compared with those 
containing stavudine between women with SIL and those 
without (12% vs 15%; p=0.41).
Bekolo et al (Cameroon, 2016)35 also reported a 
decreased risk of cervical lesions among HAART receivers. 
After controlling for age and other covariates, women in 
the HAART group had a 67% reduction in the odds of 
cervical lesions compared with the community group 
(adjusted OR=0.33; 95% CI 0.15 to 0.73; p=0.006).
Mwakigonja et al (Tanzania, 2012)36 identified immu-
nodeficiency as the main determinant of the presence 
of CIN+ in HIV-infected women: CD4 count >350 cells/
mm3 (OR=0.3; 95% CI 0.2 to 0.6) or ≥200–350 cells/mm3 
(OR=0.6; 95% CI 0.4 to 1.0) (Ref: <200 cells/mm3 CD4).
One study, Katumba et al (South Africa, 2010) reported 
that women who did not use HAART had more abnormal 
results compared with those who used HAART (p<0.028), 
although no confounders were adjusted for.
Two longitudinal studies reporting on progression/
regression of cervical disease in women with HIV infec-
tion on HAART were identified. There was a lack of 
harmony in how regression/ progression was consid-
ered. A prospective observational study conducted in 
South Africa by Firnhaber et al (2010)37 suggested that 
HAART was associated with a robust reduction in the 
incidence and progression of cervical disease (adjusted 
IRR=0.55; 95% CL 0.37 to 0.80). The study sensitivity 
analyses confirmed that the result was not dependent on 
the length of HAART exposure and this significant effect 
of HAART was only seen in women with CD4 counts 
of <350 cells/mm3.34 ASC-US (atypical squamous cells 
of undetermined significance) results were classified as 
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LSIL results, while ASC-H results were classified as HSIL 
results.
A smaller magnitude of effect was found by Omar et 
al (South Africa, 2011)38 (HR=0.72; 95% CL 0.52 to 0.99) 
using time-varying CD4 counts as a covariate in the multi-
variate model of progression. Progression was defined 
either as a subsequent smear with a cytological diagnosis 
of ASCH, HSIL or worse in women who had a previous 
normal or LSIL smear with an interval between smears 
of >5.5 months.
One study was identified on HAART and regression of 
cervical disease. A large prospective cohort study from 
Soweto, South Africa undertaken by Adler et al (2012)39 
reported that HAART positively affected the natural 
history of cervical disease in women with HIV infection 
and a multivariate marginal models analysis identified a 
significantly increased likelihood (OR=2.61; 95% CI 1.75 
to 3.89; p<0.0001) of regression of cervical lesions among 
women on HAART. Regression was defined as a subse-
quent improvement in cytological results from normal, 
ASC-US, LSIL, ASC-H, HSIL and cancer.
Other studies reported specifically on the duration of 
HAART and SIL. Kelly et al (South Africa, 2017)27 reported 
that CIN 2+ prevalence was higher among short-duration 
antitretroviral therapy  users <2 years (adjusted OR=1.99; 
95% CI 1.12 to 3.54) and  naive participants (adjusted 
OR=1.87; 95% CI 1.11 to 3.17) in South Africa. De Vuyst et al 
(Kenya, 2012)25 reported that the prevalence of CIN 2 and 
CIN 3 did not vary across HAART non-users, HAART users 
for <2 years or ≥2 years (p for linear trend=0.416). However, 
when stratified for CD4 count categories, the prevalence 
of CIN 2/3 among HAART non-users linearly increased 
per each decrease of CD4 count category, CD4 <200; 
CD4 200–349; CD4 350–499; and CD4≥500 (p for linear 
trend=0.013) but this is not seen among women receiving 
HAART for <2 years and ≥2 years (p for linear trend=0.9 and 
0.5, respectively). Still, CD4 nadir before initiating HAART 
was unknown and HAART may have been started at a CD4 
count too low to prevent or reverse CIN 2/3. Similarly, 
Huchko et al (Kenya, 2014)30 detected a non-significant 
association between the duration of HAART and CIN 2+ 
(adjusted OR=0.98; 95% CI 0.95 to 1.00), although it was 
not adjusted for CD4 count. McKenzie (Kenya, 2011)31 did 
not find any significant correlation between the duration 
and type of HAART and SIL and the median number of 
months on HAART did not differ between women with 
normal cytology and those with SIL (14 vs 11 months; 
p=0.17).
Nevertheless, Mogtomo et al (Cameroon, 2009)30 
observed that while LSIL incidence in wowmen with HIV 
infectionunder HAART therapy decreased from 8.6% 
(three cases) to 5.7% (two cases) the first 10 months of 
HAART use, it increased to 11.4% (four cases) after 10 
months. In contrast, HSIL cases decreased from 14.3% 
(n=5) to 5.7% to 2.8% (n=1) after 10 months.
Capo Chichi et al (2016)40 in Benin reported that 
cervical dysplasia was observed in 4/86 (5%) of women 
living with HIV on HAART, in whom after 2 years no new F
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cases of cervical dysplasia were reported, nor were the 
HPV genotypes present at baseline there after 2 years.
A cross-sectional study from Ethiopia (Gedefaw et al 
2013) showed that the presence of precancerous lesions 
was inversely associated with HAART: patients under 
HAART at the moment of the study (not specifying the 
duration of the treatment) were 48% less likely to have 
precancerous cervical cancer lesions than those who were 
not on HAART (adjusted OR=0.52, 95% CI 0.35 to 0.92; 
p=0.015).41
One prospective study assessed CIN 2+ incidence. Kelly 
et al (South Africa, 2017)27 reported that CIN 2+ inci-
dence was reduced among women on HAART (adjusted 
O= 0.39;95% CI 0.15 to 1.01).
Four studies contrasted in their reported results 
concerning the protective effect of higher CD4+ count 
nadir, prior to HAART initiation, on the onset of cervical 
disease. Huchko et al (Kenya, 2014)30 reported that CD4+ 
nadir over 500 cells/mm3 was associated with a reduced 
detection of CIN 2+ (adjusted OR=0.61, 95% CI 0.38 to 
0.97) in the overall group, but current CD4+ was only asso-
ciated with reduced detection of CIN 2+ among HAART 
non-users (adjusted OR=0.42; 95% CI 0.22 to 0.80).42 
This finding is compatible with the immune driven trend 
between CD4+ and a positive cervical screening among 
women with HIV infection observed by Ononogbu et al 
(Nigeria, 2013),43 which reported a decreasing risk with 
increasing CD4 count: RR=0.5 (95% CI 0.3 to 0.7) for 
CD4 count 300 to <450; RR=0.5 (95% CI 0.3 to 0.7) for 
450 to <650; and RR=0.3 (95% CI 0.2 to 0.6) for ≥650.
A prospective observational study of 601 HIV-seropos-
itive women conducted by Firnhaber et al (South Africa, 
2012) suggested that the effect of baseline HAART expo-
sure was strongly modified by baseline CD4 count when 
initiating HAART in women with CD4 counts <350 cells/
mm3. A RR=0.47 (95% CI 0.30 to 0.73) was found in 
women initiating HAART with CD4 counts <350 cells/
mm3 compared with RR=0.84 (95% CI 0.42 to 1.72) in 
women with baseline CD4 counts ≥350 cells/mm3.
Only one study reported baseline CD4 count not to be 
significant. Jacquet et al (Ivory Coast, 2014)44 reported 
that the baseline CD4 count at the time of first clinical 
follow-up, which could be interpreted as a proxy for nadir 
CD4 count, was not found to be significantly associated 
with CIN+ in the multivariate model (table 3).
epidemiological association between hAArt and ICC
Only two studies were found that assessed the effect of 
HAART on cervical cancer (table 3). An age-adjusted 
population-level evaluation of the effect of antiretroviral 
therapy on cancer incidence in Kyadondo County, Uganda 
(1999–2008), revealed that the increase in population-level 
HAART coverage over time did not affect the incidence of 
invasive cervical cancer (IRR=1.02; 95% CI 0.98 to 1.05).45 
However, Bogaert et al (South Africa, 2013) reported that 
patients on HAART had not only less CIN 1 (p=0.018) 
and CIN 2 (p=0.18) but also less ICC (p=0.019) than their 
untreated counterparts, despite similar mean CD4 count.
dIsCussIOn
The findings of our systematic review suggest a positive 
impact of HAART duration, in conjunction and inter-
action with CD4 count, on reducing the prevalence of 
HR HPV. Our review also illustrates how untreated people 
living with HIV with low CD4 count may be at increased risk 
of being or remaining infected with HR HPV compared 
with those treated with HAART. Moreover, our findings 
support the hypothesis that the greatest treatment effect 
might be seen among women starting at the lowest CD4 
count, since higher CD4 count might be associated with 
lower incidence of CIN 2+, thereby reducing the possible 
treatment effect of HAART.
The literature identified in this systematic review 
suggests that CD4 count may have a more instrumental 
role in cervical oncogenesis or the integration of the 
latent reservoir throughout the body than either HAART 
use or the treatment duration on the prevalence of CIN 
2 and CIN 3.
Surprisingly, we were unable to retrieve any studies 
that assess the impact of HAART on cervical disease 
and HPV infection across different types of HIV infec-
tions. It therefore remains unknown whether the effect 
of HAART differs between patients with HIV-1, HIV-2 or 
dual infection. HIV-2 infection and dual infection are 
highly prevalent in sub-Saharan Africa, predominantly 
in Western Africa in countries like Guinea Bissau, Ivory 
Coast, Mali and Burkina Faso.46
The sample size of the studies included in this review 
greatly varies, rendering it difficult to assess and compare 
strength of associations. Due to various difficulties, such as 
financial and ethical considerations linked to the conduct 
of RCTs, evidence is mostly based on retrospective or 
cross-sectional studies, which do not fulfil the causal crite-
rion of temporality. Heterogeneity in the sensitivity or 
specificity of screening methods may also render results 
less comparable. Cervical cytology, which has a clinical 
sensitivity between 55% and 65% for detection of histo-
pathologically confirmed 'true disease status'47 along with 
low interobserver or intraobserver true correlation can 
result in even one grade of misclassification introducing a 
bias in studies assessing regression or incidence of SIL in 
women on HAART. Moreover, a recent study in Kenya has 
reported that the sensitivity of VIA is affected in women 
on HAART and by CD4 count,48 which in studies ascer-
taining disease using colposcopy with biopsy solely in 
cases when lesions appeared suspicious for CIN 2+, may 
have led to under-ascertainment of true disease: sensitivity 
89.9% (95% CI 82.2% to 95.0%) in women under 35 and 
78.6% (95% CI 63.2% to 89.7%) in women above 35.47
Our findings derived from the sub-Saharan context 
contrast with the conclusion of a systematic review of 
studies from industrialised settings suggesting a largely 
inconsistent impact of HAART on reducing the incidence 
and progression and facilitating the regression of HPV 
infection and cervical abnormalities.49 This discrepancy 
may be attributed to the greater access in industrialised 
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settings to frequent cytological screening, thereby making 
the potential benefits of HAART less apparent.
One of the few retrieved prospective studies exploring 
the impact of HAART on SIL incidence and progres-
sion only reported a significant association in women 
with CD4 counts <350 cells/mm3. Apart from the inclu-
sion criteria providing heterogeneity in baseline profiles 
of women, different potential confounders have been 
adjusted for in studies addressing the same outcome. Not 
all studies control for hormonal/barrier contraception 
use, HIV viral load, CD4 count baseline or the number of 
sexual partners, therefore residual confounding cannot 
be excluded. In addition, the duration of follow-up may 
be too short and not always detailed in articles.
Clinical and public health implications
The lack of statistically significant associations observed in 
this review between duration of HAART intake and reduc-
tion of CIN 2+ in women initiating HAART at an earlier 
CD4 count initiation suggests the importance of continued 
follow-up with cervical cytological and/or histological 
screening. Even after HAART initiation and immune 
reconstitution, lesions remain prevalent and progression of 
disease should be studied further to allow best timing of 
a screening schedule.
Although current HAART guidelines in industrialised 
countries promote biannual cervical cancer screening 
in the first year following HIV diagnosis and annually 
thereafter, in the absence of evidence-based knowledge 
in sub-Saharan African women, it may be advisable to 
address the following research gaps before suggesting the 
relevance of the guideline in this population. In the mean 
time, a cautionary approach may be employed and bian-
nual cervical screening continued, if feasible.
research gaps
The dearth of studies on duration and initiation of 
HAART at an earlier CD4 count and the consensus on 
findings preclude policy makers from developing local 
guidelines. Moreover, due to the changes in recommen-
dations for HAART start, women in sub-Saharan Africa 
at the time of the studies were more likely to have low 
CD4 counts, whereas in the future they will be initiating 
HAART in a far less immunosuppressed state.
Future studies should preferably be prospective in 
design. This will allow a better follow-up of patients at 
different points in time and fulfil the criterion of tempo-
rality for causality. Moreover, including nested case-control 
studies within cohort follow-up will allow robust interme-
diary evidence for such research questions. Studies should 
also elucidate the association between cervical HIV DNA 
and HPV incidence/prevalence, or cervical dysplasia.
The exploration of an association between HAART 
and cervical cancer warrants large cancer epidemiolog-
ical studies. Previously, the lack of effect of HAART on 
the prevalence on cervical cancer can be ascribed to the 
high mortality associated with AIDS. Despite improved 
longevity, and in settings with a life expectancy that exceeds 
the average age of cervical cancer onset, one study to date 
from our review suggested that, thanks to extensive HAART 
programmes, decrease in cervical cancer incidence can be 
expected.50
Finally, women with HIV-HPV coinfections may be at 
risk for immune-modulating helminthic, tuberculosis 
and malarial infections51, which may compromise the 
positive impact that HAART may have on clearing cervical 
lesions. Their synergistic interactions in the post-HAART 
era should be elucidated.
COnClusIOn
Access to HAART in sub-Saharan Africa has dramatically 
increased over the past decade, improving life expectancy 
for women living with HIV. This in turn requires urgent 
clarification of the impact of HAART on the development 
of cervical precancerous states and cancer.
Whilst the preponderance of studies suggests that 
women on HAART are less likely to have SIL, for ICC, 
evidence remains scarce and inconclusive. However, our 
review imputes a more significant role of CD4 count or 
the CD4 count at which HAART is initiated, the timing of 
HAART in relation to immunosuppression on HR HPV 
genotype and CIN 2/3 prevalence, than to HAART use, 
irrespective of its duration. The scarce evidence shows 
that the positive impact of HAART is only felt in women 
with CD4 counts of <350 cells/mm3.3
Given the current limited evidence available to assist 
policy makers in developing local guidelines and preven-
tion and treatment strategies for cervical cancer among 
women with HIV infection on HAART, a tailored screening 
protocol cannot be established. Longer term surveillance 
data on women who are HIV positive at different levels of 
immunosuppression is crucial to determine the effect of 
HAART on CIN 2+.
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